Crinetics Pharmaceuticals, Inc.
CRNX
Hisse Senetlerindeki Sıralama
#2238
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Hisse Fiyatı
$84.95
Son senkronizasyon: 2026-09-01
Piyasa Değeri
$9.00B
Değişim (1 gün)
0.00%
Değişim (1 yıl)
98.25%
Ülke
US
Ticaret Crinetics Pharmaceuticals, Inc. (CRNX)
Kategori
Healthcare
Crinetics Pharmaceuticals, Inc. (CRNX) için tedavüldeki hisse sayısı
June 2026 itibarıyla tedavüldeki hisse sayısı: 105.56M
Crinetics Pharmaceuticals, Inc. şirketinin son finansal raporlarına ve hisse fiyatına göre, mevcut tedavüldeki hisse sayısı 105.56M'dir. December 2023 sonunda şirketin 58.07M tedavüldeki hissesi vardı. Tedavüldeki hisse sayısı genellikle hisse bölünmeleri ve hisse geri alımları ile etkilenir.
Crinetics Pharmaceuticals, Inc. (CRNX) için 2016 - 2026 tarihleri arasındaki hisse geçmişi
Her yıl sonunda tedavüldeki hisse sayısı
| Yıl | Tedavüldeki Hisse Sayısı | Değiştir |
|---|---|---|
| 2026 (TTM) | 105.56M | 30.67% |
| 2024 | 80.78M | 39.11% |
| 2023 | 58.07M | 11.71% |
| 2022 | 51.98M | 35.24% |
| 2021 | 38.44M | 26.23% |
| 2020 | 30.45M | 25.95% |
| 2019 | 24.18M | 99.10% |
| 2018 | 12.14M | -12.51% |
| 2017 | 13.88M | 0.00% |
| 2016 | 13.88M | 0.00% |
Benzer şirketler veya rakipler için tedavüldeki hisse sayısı
| Şirket | Tedavüldeki Hisse Sayısı | Fark | Ülke |
|---|---|---|---|
| 253.90M | 140.53% |
US
|
|
| 396.00M | 275.14% |
US
|
|
| 478.91M | 353.69% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -41.09% |
NL
|
